Caribou initiates dose expansion of CB-010 ANTLER trial in second-line LBCL patients

Caribou Biosciences, Inc.

CB-010 is first allogeneic CAR-T evaluated in second-line LBCL, per company.
Dose expansion will test 80x10^6 and 120x10^6 CAR-T cells in ~30 patients.
In dose escalation, no DLTs at dose level 3; at dose level 1, 6/6 complete response, 3/6 at 6 months, 2/6 at 12 months.
Company expects safety/efficacy update in H2 2023 with data from at least 15 dose-escalation patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.